By all measures, the addition of nab-paclitaxel to gemcitabine for the treatment of patients with advanced pancreatic cancer improved the outcomes in comparison to patients who received only gemcitabine, according to the results of a phase III study led by Dr Daniel Von Hoff, TGen Distinguished Professor and Physician-In-Chief, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership with the Translational Genomics Research Institute (TGen) and Scottsdale Healthcare. Read more here.
Study mentioned: Von Hoff DD, et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013 Oct 16. [Epub ahead of print] PMID: 24131140
No comments:
Post a Comment